Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.51 |
| ▸ | NCF1 | P14598 | 5/20 | 0.50 |
| ▸ | ADRB2 | P07550 | 4/20 | 0.50 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.47 |
| ▸ | HTR2A | P28223 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.47 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.47 |
| ▸ | HTR7 | P34969 | 1/20 | 0.43 |
| ▸ | LATS1 | O95835 | 1/20 | 0.42 |
| ▸ | AURKA | O14965 | 1/20 | 0.42 |
| ▸ | PARP1 | P09874 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4754853 | 0.78 | KDR (0.54) | KDRNCF1ADRB2MAPTHTR2A | |
| SCHEMBL5124241 | 0.77 | KDR (0.68) | KDRNCF1ADRB2ADRB1HTR2A | |
| SCHEMBL31521684 | 0.77 | KDR (0.68) | KDRNCF1ADRB2ADRB1HTR2A | |
| SCHEMBL20111997 | 0.77 | HTR2A (0.51) | NCF1ADRB2MAPTHTR2AHTR2C | |
| Hydrochloric Acid SCHEMBL9128302 | 0.75 | KDR (0.66) | KDRNCF1ADRB2ADRB1HTR2A | |
| SCHEMBL4751829 | 0.75 | KDR (0.58) | KDRNCF1ADRB2ADRB1LATS1 | |
| SCHEMBL4753880 | 0.75 | KDR (0.61) | KDRNCF1ADRB2MAPTLATS1 | |
| Hydrochloric Acid SCHEMBL29691597 | 0.75 | NCF1 (0.50) | NCF1ADRB2MAPT | |
| Hydrochloric Acid SCHEMBL26679882 | 0.75 | NCF1 (0.50) | NCF1ADRB2MAPT | |
| SCHEMBL2884262 | 0.72 | NCF1 (0.79) | NCF1ADRB2MAPTADRB1HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-101466681-A | Tumor necrosis factor alpha inhibitors and their use in the treatment of human diseases | AVANIR PHARMACEUTICALS (US) | 2009-06-24 | — | — | CN | disclosed |
| EP-1996553-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | Avanir Pharmaceuticals (US) | 2008-12-03 | — | — | EP | disclosed |
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2008-06-12 | — | — | US | disclosed |
| WO-2007109251-A2 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | AVANIR PHARMACEUTICALS (US) | 2007-09-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139551-A1 | TUMOR NECROSIS FACTOR ALPHA INHIBITORS AND THEIR USE IN THE TREATMENT OF HUMAN DISEASES | TNF, TNFRSF1A, TNFRSF9 | KDR 768/4885NCF1 35/4885ADRB2 1830/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.